.Pharmacolibrary.Drugs.ATC.A.A04AA05

Information

Palonosetron is a selective 5-HT3 receptor antagonist used primarily for the prevention of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative recovery. It is a long-acting antiemetic drug approved and widely used today in clinical practice.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult subjects after a single intravenous dose.

References

1. Lee, S, et al., & Jeong, S (2019). Population pharmacokinetics of palonosetron and model-based assessment of dosing strategies. Journal of anesthesia 33(3) 381–389. DOI:10.1007/s00540-019-02641-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30976908

2. Rapoport, B, & Smit, T (2017). Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy. Expert opinion on drug safety 16(6) 697–710. DOI:10.1080/14740338.2017.1325868 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28460548

3. Stoltz, R, et al., & Parisi, S (2004). Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. Journal of clinical pharmacology 44(5) 520–531. DOI:10.1177/0091270004264641 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15102873

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)